Dasatinib Drugs Market, By Type, By Indication, By Distribution Channel, By Geography

Description

Dasatinib Drugs Market is estimated to be valued at USD 1,646.1 Mn in 2025 and is expected to reach USD 2,475.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,646.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.00%	2032 Value Projection:	USD 2,475.1 Mn

Dasatinib is a potential tyrosine kinase inhibitor that has revolutionized the treatment landscape for certain types of cancer. Initially developed as a targeted therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib specifically targets and inhibits the BCR-ABL protein, suppressing the growth and proliferation of cancer cells. With remarkable efficacy, dasatinib has significantly improved outcomes and increased survival rates in patients with these malignancies. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management. Ongoing research and clinical trials are exploring the potential of dasatinib in combination therapies, paving the way for further advancements in cancer treatment strategies.

Market Dynamics:

The increasing prevalence of cancer, favorable clinical outcomes, and expansion of approved indications are anticipated to drive the growth of the global dasatinib drugs market over the forecast period. Moreover, the development of targeted therapies is also expected to boost the growth of the global dasatinib drugs market over the forecast period. Expansion into emerging markets, combination therapies, pediatric indications, and the development of generic versions are expected to create growth opportunities for the global dasatinib drugs market growth during the forecast period.

However, the high cost of treatment, stringent regulatory requirements, potential adverse effects, the development of resistance are expected to hamper the growth of the dasatinib drugs market over the forecast period.

Key features of the study:

This report provides an in-depth analysis of the global dasatinib drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dasatinib drugs market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dasatinib drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dasatinib drugs market

Detailed Segmentation:

Dasatinib Drugs Market, By Type:
- 20 mg
- 50 mg
- 70 mg
Dasatinib Drugs Market, By Indication:
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Others
Dasatinib Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Dasatinib drugs market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles:
- Bristol-Myers Squibb
- MSN Labs
- Lupin
- Dr. Reddy's Laboratories
- Hetero Labs
- MANUS AKTTEVA BIOPHARMA LLP
- Alembic Pharma
- JINLAN Pharm-Drugs Technology Co., Ltd.
- Reddy's Laboratories
- Zhejiang Hisun Pharma

Product Code: CMI5963

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Indication
- Market Snippet, By Distribution channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Increasing prevalence of cancer
- Restraints
Increasing product recall
- Opportunities
Expansion into emerging markets
Combination therapies
Pediatric indications
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Dasatinib Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Dasatinib Drugs Market, By Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
70 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Dasatinib Drugs Market, By Indication, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chronic Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Acute Lymphoblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Dasatinib Drugs Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Dasatinib Drugs Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - South Africa
  - Central Africa

9. Competitive Landscape

Bristol-Myers Squibb
- Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- MSN Labs
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Hetero Labs
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Alembic Pharma,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- JINLAN Pharm-Drugs Technology Co., Ltd.,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Reddy's,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Zhejiang Hisun Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Analyst Views

10. Section

Research Methodology
About us